Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024

 
• By Joseph Haas

Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.

Eye
Aldeyra will launch new Phase III study in dry eye to respond to FDA CRL

More from Clinical Trials

More from R&D